<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04711226</url>
  </required_header>
  <id_info>
    <org_study_id>AT-1501-I203</org_study_id>
    <secondary_id>AT-1501-I203</secondary_id>
    <nct_id>NCT04711226</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation</brief_title>
  <official_title>An Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Adults With Type 1 Diabetes Undergoing Islet Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anelixis Therapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eledon Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, tolerability and efficacy of AT-1501 in an&#xD;
      immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety, tolerability and efficacy of AT-1501 in an&#xD;
      immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant. This&#xD;
      study will also provide valuable data with respect to its potential additional uses in&#xD;
      autoimmunity and solid organ transplant. This is a single arm open-label study and up to 6&#xD;
      participants will be recruited at a single center in Canada.&#xD;
&#xD;
      The objectives include:&#xD;
&#xD;
        -  To assess the safety and tolerability of immunomodulation with AT-1501, in combination&#xD;
           (AT+) with rabbit anti-thymoglobulin (ATG), etanercept and mycophenolate mofetil&#xD;
           (MMF/EC-MPS) in adults with T1D undergoing islet cell transplant.&#xD;
&#xD;
        -  To assess the efficacy of immunomodulation with AT-1501 in adults with T1D undergoing&#xD;
           islet cell transplant.&#xD;
&#xD;
      The duration of treatment may vary from participant to participant and could be up to 20&#xD;
      months. Participants may receive up to 2 islet cell transplants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 19, 2021</start_date>
  <completion_date type="Anticipated">June 2026</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety- Adverse Events (AE) and Adverse Events of Special Interest (AEoSI)</measure>
    <time_frame>Accessed from date of transplant through 1 year post transplant for approximately 2 years</time_frame>
    <description>Incidence of adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy- Insulin independence</measure>
    <time_frame>Days 75 , Day 365 post-first transplant, and final transplant and 1 year after discontinuation of AT-1501</time_frame>
    <description>Change in the proportion of participants that become insulin independent at Days 75 and 365 post-first, and final transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy- Graft failure</measure>
    <time_frame>Day 365</time_frame>
    <description>Proportion of participants with graft failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy- Durability of insulin independence- long term</measure>
    <time_frame>2 and 3 years after discontinuation of AT- 1501</time_frame>
    <description>Change in the proportion of participants that become insulin independent at year 2 and year 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy- HbA1c</measure>
    <time_frame>Day 365 and free of serious hypoglycemic events from Day 28 to 365 post-first transplant</time_frame>
    <description>Proportion of participants with HbA1c &lt;7.0% (53 mmol/mol) and free of serious hypoglycemic events (SHEs)&#xD;
Proportion of participants with HbA1c ≤6.5% (48 mmol/mol) and free from SHEs</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory- Hypoglycemia unawareness (using the method of Clarke)</measure>
    <time_frame>Day 75, 365, and 1, 2 and 3 years after discontinuation of AT-1501</time_frame>
    <description>Proportion of participants with hypoglycemia unawareness</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory- Glycemic lability (using CGMS)</measure>
    <time_frame>Day 75, 365, and 1, 2 and 3 years after discontinuation of AT-1501</time_frame>
    <description>Change in glycemic lability using CGMS- Continuous Glucose Monitoring System</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory- Glycemic variability (using CGMS)</measure>
    <time_frame>Day 75, 365, and 1, 2 and 3 years after discontinuation of AT-1501</time_frame>
    <description>Change in glycemic variability using CGMS- Continuous Glucose Monitoring System</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory- Albumin excretion ratio (AER)</measure>
    <time_frame>Day 365 post-first, and final transplant</time_frame>
    <description>Change in albumin excretion ratio (AER)</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory- eGRF</measure>
    <time_frame>Day 365 post-first, and final transplant</time_frame>
    <description>Change in eGRF</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory- Macroalbuminemia</measure>
    <time_frame>Day 365 post-first, and final transplant</time_frame>
    <description>Change in percent new macroalbuminemia</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory- biomarkers of tissue damage and inflammation</measure>
    <time_frame>Day -2, 3, 14, 28, 75, 175, 364</time_frame>
    <description>Biomarkers</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory -Pharmacokinetic Parameters-AUC</measure>
    <time_frame>T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.</time_frame>
    <description>Pharmacokinetics (PK) of AT-1501</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory- Pharmacokinetic Parameters-Cmax</measure>
    <time_frame>T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.</time_frame>
    <description>Pharmacokinetics (PK) of AT-1501</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory- Pharmacokinetic Parameters-CL</measure>
    <time_frame>T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.</time_frame>
    <description>Pharmacokinetics (PK) of AT-1501</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory- Pharmacokinetic Parameters- Vdss</measure>
    <time_frame>T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.</time_frame>
    <description>Pharmacokinetics (PK) of AT-1501</description>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory- Pharmacokinetic Parameters- (t1/2)</measure>
    <time_frame>T=0 (pre infusion), 1 (end of infusion), 2, 4, 8, 12, 24 and 48 hrs.</time_frame>
    <description>Pharmacokinetics (PK) of AT-1501</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>AT-1501 Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-1501</intervention_name>
    <description>AT-1501 IV infusion</description>
    <arm_group_label>AT-1501 Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women 18-65 years of age&#xD;
&#xD;
          2. A diagnosis of T1D ≥5 years with onset of disease at &lt;40 years of age&#xD;
&#xD;
          3. Involvement in intensive diabetes management as directed by an endocrinologist or&#xD;
             diabetologist with at least 3 clinical evaluations within the 12 months prior to&#xD;
             Screening; using an insulin pump or multiple daily injection (MDI) insulin therapy;&#xD;
             and, unable to achieve acceptable metabolic control because of the occurrence of&#xD;
             severe hypoglycemia&#xD;
&#xD;
          4. At least 2 unexplained SHEs not secondary to a missed meal or dosing error, etc., in&#xD;
             the 12 months prior to Screening&#xD;
&#xD;
          5. Glycosylated hemoglobin (HbA1c) level greater than 7% (53 mmol/mol) and less than 9.5%&#xD;
             (80 mmol/mol) inclusive&#xD;
&#xD;
          6. Absence of stimulated C peptide (&lt; 0.3 ng/mL) in response to a mixed meal tolerance&#xD;
             test (MMTT) measured at 60 and 90 minutes after the start of consumption&#xD;
&#xD;
          7. Reduced awareness of hypoglycemia as defined by a Clarke Score [Clarke 1995] of 4 or&#xD;
             more at the time of Screening, during the Screening period and within the last 6&#xD;
             months prior to the transplant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any previous transplant&#xD;
&#xD;
          2. HbA1c level less than 7% (53 mmol/mol)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Bornstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Eledon Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lois Kelly</last_name>
    <phone>949-238-8090</phone>
    <email>lkelly@eledon.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 10, 2021</study_first_submitted>
  <study_first_submitted_qc>January 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 15, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 1 Diabetes</keyword>
  <keyword>T1D</keyword>
  <keyword>Islet Cell Transplant</keyword>
  <keyword>AT-1501</keyword>
  <keyword>humanized blocking antibody to CD40L</keyword>
  <keyword>CD40L inhibitor</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>Glucose Metabolism Diseases</keyword>
  <keyword>Diabetes Mellitus, Type 1</keyword>
  <keyword>Endocrine System Diseases</keyword>
  <keyword>Graft</keyword>
  <keyword>Metabolic Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>Hyperglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

